Supporting information for

Modulation of the Magnetic and Photophysical Properties of 3d4f and 4f4f' Heterobimetallic Complexes Involving a Tetrathiafulvalene-Based Ligand

Haiet Douib,^{a,b} Jessica Flores Gonzalez,^a Saskia Speed,^{c,d} Vincent Montigaud,^a Bertrand Lefeuvre,^a Vincent Dorcet,^a François Riobé,^c Olivier Maury,^c Abdelkrim Gouasmia,^b Boris le Guennic,^a Olivier Cador, ^{*a} and Fabrice Pointillart^{*a}

^a Institut des Sciences Chimiques de Rennes UMR 6226 CNRS-UR1, Université de Rennes 1, 35042 Rennes Cedex, France

^b Laboratoire des Matériaux Organiques et Hétérochimie (LMOH), Département des sciences de la matière, Université Larbi Tébessi de Tébessa, Route de Constantine 12002, Tébessa, Algérie.

^c Univ Lyon, ENS de Lyon, CNRS UMR 5182, Université Claude Bernard Lyon 1, Laboratoire de Chimie, F69342, Lyon, France.

^d Departament de Química Inorgànica i Orgànica, Secció de Química Inorgànica, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain.

Olivier.cador@univ-rennes1.fr, fabrice.pointillart@univ-rennes1.fr

Experimental

Synthesis. General Procedures and Materials. The precursors $Ln(hfac)_3 \cdot nH_2O$ (Ln(III) = Pr and Nd with n = 3, Dy and Yb with n = 2; hfac⁻ = 1,1,1,5,5,5hexafluoroacetylacetonate anion),¹ Dy(tta)₃·2H₂O² and the ligand 2-{1-[2,6-di(pyrazol-1-yl)-4-methylpyridyl]-4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine (**L**) were synthesized following previously reported methods.³ All other reagents were purchased from Aldrich Co., Ltd. and used without further purification. **Synthesis of complexes 1-10.**

 $[MLn(hfac)_5(L)]_n \cdot x(CH_2Cl_2) \cdot y(C_6H_{14})$ (M=Cd, Ln=Dy, n=2, x=0 and y=0 (1); M=Zn, Ln=Dy, n=1, x=2 and y=1 (2); M=Zn, Ln=Yb, n=2, x=1 and y=2 (3); M=Mn, Ln=Dy, n=1, x=2 and y=0 (4); M=Mn, Ln=Yb, n=1, x=2 and y=0 (5); M=Co, Ln=Y, n=1, x=1 and y=0 (6); M=Co, Ln=Dy, n=1, x=2 and y=1 (7); M=Co, Ln=Yb, n=1, x=0 and y=0 (8); M=Ni, Ln=Dy, n=1, x=2 and y=1 (9); M=Ni, Ln=Yb, n=1, x=0 and y=0 (10)). 0.02 mmol of M(hfac)₂·2H₂O were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of L (0.02 mmol). After 20 min of stirring, 0.02 mmol of Ln(hfac)₃·2H₂O previously dissolved in 5 mL of CH₂Cl₂ were added to the dark red mixture. 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to dark red single crystals which are suitable for X-ray studies. Yields (1) 29 mg (71 %), (2) 30 mg (66 %),(3) 26 mg (63 %), (4) 34 mg (78 %), (**5**) 33 mg (76 %), (**6**) 29 mg (66 %), (**7**) 31 mg (69 %), (**8**) 26 mg (65 %), (**9**) 32 mg (70%) and (10) 29 mg (71%). Representative I.R.bands (KBr): 3142, 2970, 2932, 2871, 2878, 1655, 1578, 1556, 1531, 1502, 1465, 1410, 1258, 1205, 1146, 1056, 973, 797, 663 and 583 cm⁻¹. Anal. Calcd (%) for C₁₁₈H₇₀Cd₂Dy₂F₆₀N₁₆O₂₀S₁₂ (1): C 34.48, H 1.70, N 5.45; found: C 34.81, H 1.86 N, 5.29. Anal. Calcd (%) for C₆₇H₅₃Cl₄ZnF₃₀N₈O₁₀S₆Dy (2): C 35.56, H 2.34, N 4.95; found: C 35.51, H 2.26 N, 4.89. Anal. Calcd (%) for C₁₁₉H₇₂Zn₂Yb₂F₆₀N₁₆O₂₁S₁₂Cl₂ (**3**): C 34.54, H 1.74, N 5.42; found: C 34.91, H 1.99 N, 5.29. Anal. Calcd (%) for C₆₁H₃₉MnDyF₃₀N₈O₁₀S₆Cl₄ (4): C 33.80, H 1.80, N 5.17; found: C 33.71, H 1.86 N, 5.09. Calcd (%) for C₆₁H₃₉MnYbF₃₀N₈O₁₀S₆Cl₄ (**5**): C 33.64, H 1.79, N 5.15; found: C 33.61, H 1.86 N, 5.19. Anal. Calcd (%) for C₆₇H₅₃Cl₄CoF₃₀N₈O₁₀S₆Y (**6**): C 36.84, H 2.43, N 5.13; found: C 36.71, H 2.36 N, 5.05. Anal. Calcd (%) for C₆₇H₅₃Cl₄CoF₃₀N₈O₁₀S₆Dy (7): C 35.64, H 2.35, N 4.97; found: C 35.61, H 2.30 N, 4.79. Anal. Calcd (%) for C₅₉H₃₅CoF₃₀N₈O₁₀S₆Yb (8): C 35.22, H 1.74, N 5.57; found: C 35.61, H 1.99 N, 5.29. Anal. Calcd (%) for C₆₇H₅₃Cl₄NiF₃₀N₈O₁₀S₆Dy

(9): C 35.65, H 2.35, N 4.97; found: C 35.71, H 2.33 N, 4.78. Anal. Calcd (%) for $C_{59}H_{35}NiF_{30}N_8O_{10}S_6Yb$ (10): C 35.22, H 1.74, N 5.57; found: C 35.52, H 1.96 N, 5.37 **Synthesis of the complex [ZnDy(tta)₂(hfac)₃(L)]·(CH₂Cl₂) (11).** 10.4 mg of Zn(hfac)₂·2H₂O (0.02 mmol) were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of **L** (0.02 mmol). After 20 min of stirring, 17.2 mg of Dy(tta)₃·2H₂O (0.02 mmol) previously dissolved in 5 mL of CH₂Cl₂ were added to the dark red mixture. 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to red single crystals which are suitable for X-ray studies. Yield 19 mg (44 %). I.R. (KBr): 3138, 2965, 2929, 2874, 2878, 1657, 1604, 1582, 1534, 1504, 1462, 1411, 1355, 1308, 1254, 1201, 1144, 1058, 970, 792, 721, 660 and 581 cm⁻¹. Anal. Calcd (%) for C₆₆H₄₃Cl₂DyZnF₂₄N₈O₁₀S₈: C 37.37, H 2.03, N 5.28; found: C 37.51, H 2.16 N, 5.09.

Synthesis of the complex [Cu(hfac)(CH₃OH)(L')]·0.5(C₆H₁₄) (12). 10.4 mg of Cu(hfac)₂·2H₂O (0.02 mmol) were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of L (0.02 mmol). After 20 min of stirring, 16.4 mg of Dy(hfac)₃·2H₂O (0.02 mmol) previously dissolved in 5 mL of CH₂Cl₂ were added to the dark red mixture. Few drops of MeOH were finally added leading to the formation of an orange solution. 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to orange single crystals which are suitable for X-ray studies. Yield 11 mg (64 %). I.R. (KBr): 3146, 2967, 2932, 2872, 1654, 1558, 1534, 1504, 1463, 1413, 1258, 1206, 1145, 799, 662 and 586 cm⁻¹. Anal. Calcd (%) for C₃₁H₃₁CuF₆N₁O₃S₆: C 43.08, H 3.59, N 1.62; found: C 43.01, H 3.66 N, 1.59.

Synthesis of the complex [Cu(H₂O)Dy(hfac)₄(L)]·[Dy(hfac)₄]·(CH₂Cl₂) (13). This compound was obtained using the same experimental protocol as for 12 except that no methanol was used. Slow diffusion of *n*-hexane leads to purple single crystals which are suitable for X-ray studies. Yield 38 mg (66 %). I.R. (KBr): 3138, 3093, 2967, 2934, 2876, 1654, 1617, 1575, 1529, 1492, 1468, 1259, 1208, 1144, 793, 664 and 585 cm⁻¹. Anal. Calcd (%) for C₇₅H₄₀Cl₂CuDy₂F₄₈N₈O₁₇S₆: C 31.15, H 1.38, N 3.88; found: C 31.11, H 1.36 N, 3.93.

 $[Pr(hfac)_3(L)]_2 \cdot 0.25(CH_2Cl_2) \cdot 0.5(C_6H_{14})$ (14). 32.7 mg of $Pr(hfac)_3 \cdot 3H_2O$ (0.04 mmol) were dissolved in 10 mL of CH_2Cl_2 and then added to a solution of 10 mL of CH_2Cl_2 containing 14.8 mg of L (0.02 mmol). After 1 h of stirring, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to orange single crystals

which are suitable for X-ray studies. Yield 25 mg (41 %). Anal. Calcd (%) for $C_{101.25}H_{73.5}Cl_{0.5}Pr_2F_{36}N_{16}O_{12}S_{12}$: C 39.52, H 2.39, N 7.29; found: C 39.49, H 2.36 N, 7.24. I.R. (KBr): 2957, 2870, 2853, 1654, 1574, 1557, 1532, 1506, 1465, 1410, 1258, 1207, 1146, 1099, 1057, 975, 799, 660 and 587 cm⁻¹.

[**Dy**_{1.21}**Nd**_{0.79}(**hfac**)₆(**L**)]·2(**CH**₂**Cl**₂)·(**C**₆**H**₁₄) (15). 16.4 mg of Nd(hfac)₃·3H₂O (0.02 mmol) were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of **L** (0.02 mmol). After 15 min of stirring at room temperature, 16.4 mg of Dy(hfac)₃·2H₂O (0.02 mmol) dissolved in 5 mL of CH₂Cl₂ were added to the orange mixture leading to a deep red solution. After additional 15 min of stirring, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 31 mg (61 %). Anal. Calcd (%) for C₇₂H₅₄Cl₄Dy_{1.21}F₃₆N₈Nd_{0.79}O₁₂S₆: C 33.87, H 2.18, N 4.39; found: C 33.59, H 2.16 N, 4.48. I.R. (KBr): 3146, 2972, 2934, 2878, 1652, 1558, 1533, 1500, 1464, 1411, 1257, 1208, 1145, 1099, 1058, 974, 800, 661 and 585 cm⁻¹.

[**Dy**_{1.11}**Nd**_{0.89}(**tta**)₃(**hfac**)₃(**L**)] (**16**). 16.4 mg of Nd(hfac)₃·3H₂O (0.02 mmol) were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of **L** (0.02 mmol). After 15 min of stirring at room temperature, 17.2 mg of Dy(tta)₃·2H₂O (0.02 mmol) dissolved in 5 mL of CH₂Cl₂ were added to the orange mixture leading to a deep red solution. After additional 15 min of stirring, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 31 mg (61 %). Anal. Calcd (%) for C₇₃H₄₅Dy_{1.11}F₂₇N₈Nd_{0.89}O₁₂S₉: C 37.49, H 1.93, N 4.79; found: C 37.01, H 1.86 N, 4.48. I.R. (KBr): 3140, 2964, 2927, 2874, 1655, 1603, 1582, 1535, 1505, 1460, 1411, 1355, 1307, 1253, 1200, 1142, 1058, 969, 792, 720, 659 and 582 cm⁻¹.

[Yb1.04Nd0.96(hfac)6(L)] (17). 16.4 mg of Nd(hfac)₃·3H₂O (0.02 mmol) were dissolved in 5 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of **L** (0.02 mmol). After 15 min of stirring at room temperature, 16.6 mg of Yb(hfac)₃·2H₂O (0.02 mmol) dissolved in 5 mL of CH₂Cl₂ were added to the orange mixture leading to a deep red solution. After additional 15 min of stirring, 40 mL of *n*hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 30 mg (64 %). Anal. Calcd (%) for C₇₀H₅₀F₃₆N₈Yb_{1.04}Nd_{0.96}O₁₂S₆: C 35.17, H 2.09, N 4.69; found: C 35.01, H 1.96 N, 4.78. I.R. (KBr): 3142, 2971, 2940, 2878, 1652, 1558, 1533, 1501, 1464, 1410, 1259, 1206, 1145, 1099, 1060, 975, 799, 661 and 583 cm⁻¹.

[Nd₂(hfac)₆(L)] (18). 32.8 mg of Nd(hfac)₃·3H₂O (0.04 mmol) were dissolved in 10 mL of CH₂Cl₂ and then added to a solution of 10 mL of CH₂Cl₂ containing 14.8 mg of L (0.02 mmol). After 15 min of stirring at room temperature, the orange solution was refluxed for 1h leading to a deep red solution. After additional 15 min of stirring at room temperature, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 32 mg (68 %). Anal. Calcd (%) for C₇₀H₅₀F₃₆N₈Nd₂O₁₂S₆: C 35.59, H 2.12, N 4.75; found: C 35.11, H 2.00 N, 4.80. I.R. (KBr): 3142, 2970, 2938, 2878, 1652, 1558, 1533, 1500, 1465, 1410, 1257, 1206, 1145, 1099, 1058, 975, 798, 661 and 585 cm⁻¹.

[YbPr(hfac)₆(L)] (19). Method a. 16.4 mg of $Pr(hfac)_3 \cdot 3H_2O$ (0.02 mmol) were dissolved in 5 mL of CH_2Cl_2 and then added to a solution of 10 mL of CH_2Cl_2 containing 14.8 mg of L (0.02 mmol). After 15 min of stirring at room temperature, 16.6 mg of Yb(hfac)_3 \cdot 2H_2O (0.02 mmol) dissolved in 5 mL of CH_2Cl_2 were added to the orange mixture leading to a deep red solution. After additional 15 min of stirring, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 33 mg (71 %).

Method b. 15.4 mg of single crystals of **14** (0.005 mmol) were dissolved in 10 mL of CH_2Cl_2 and then added to a solution of 5 mL of CH_2Cl_2 containing 8.3 mg of $Yb(hfac)_3 \cdot 2H_2O$ (0.01 mmol) was added to the orange mixture leading to a deep red solution. After additional 15 min of stirring, 40 mL of *n*-hexane were layered at room temperature in the dark. Slow diffusion leads to deep red single crystals which are suitable for X-ray studies. Yield 18 mg (80 %).

Anal. Calcd (%) for C₆₄H₃₆YbF₃₆N₈PrO₁₂S₆: C 33.40, H 1.57, N 4.87; found: C 34.00, H 1.66 N, 4.62. I.R. (KBr): 3142, 2970, 2937, 2878, 1652, 1558, 1533, 1501, 1465, 1411, 1258, 1206, 1145, 1100, 1057, 973, 799, 660 and 585 cm⁻¹.

Crystallography. Single crystals of **1**, **3**, **4**, **6**, **8**, **11-13**, **15-19** were mounted on a D8 VENTURE Bruker-AXS diffractometer for data collection (MoK_{α} radiation source, $\lambda = 0.71073$ Å), from the Centre de Diffractométrie X (CDIFX), Université de Rennes 1, France while single crystal of **14** was mounted on a APEXII Bruker-AXS diffractometer (Tables S1 and S2).

Structures were solved with a direct method using the SHELXT program⁴ and refined with a full matrix least-squares method on F² using the SHELXL-14/7 program⁵. For all the other compounds (**2**, **5**, **7**, **9** and **10**), the cells were record on the D8 VENTURE Bruker-AXS diffractometer (Table S3). SQUEEZE procedure of PLATON⁶ was performed for structures containing large solvent accessible voids in which residual peak of diffraction were observed. The ratio of metallic center on each cristallographic site were fixed from the values determined by Energy Dispersive Spectrometry. Crystallographic data are summarized in Tables S1-S3. Complete crystal structure results as a CIF file including bond lengths, angles, and atomic coordinates are deposited as Supporting Information.

Physical Measurements. The elemental analyses of the compounds were performed at the Centre Régional de Mesures Physiques de l'Ouest, Rennes. The Ln/Ln' ratio of the compounds 15-17 were determined using SEM (Scanning Electron Microscopy). All observations and measurements were carried out with a JEOL JSM 6400 scanning electron microscope (JEOL Ltd., Tokyo, Japan) with an EDS (Energy Dispersive Spectrometry) analysis system (OXFORD Link INCA). The voltage was kept at 9 kV, and the samples were mounted on carbon stubs and coated for 5 min with a gold/palladium alloy using a sputter coater (Jeol JFC 1100). Each ratio given in the text is the average value between at least three measurements. This analysis has been performed by the "Centre de Microscopie Electronique à Balayage et microAnalyse (CMEBA)" from the University of Rennes 1 (France). Cyclic voltammetry was carried out in CH₂Cl₂ solution, containing 0.1 M N(C₄H₉)₄PF₆ as supporting electrolyte. Voltammograms were recorded at 100 mVs⁻¹ at a platinum disk electrode. The potentials were measured *versus* a saturated calomel electrode (SCE). Absorption spectra were recorded on a Varian Cary 5000 UV-Visible-NIR spectrometer equipped with an integration sphere. The luminescence spectra were measured using a Horiba-Jobin Yvon Fluorolog-3® spectrofluorimeter, equipped with a three slit double grating excitation and emission monochromator with dispersions of 2.1 nm/mm (1200 grooves/mm). The steady-state luminescence was excited by unpolarized light from a 450 W xenon CW lamp and detected at a 90° angle by either a Hamamatsu R928 photomultiplier tube (300-800 nm) or an InGaAs near -infrared detector (850-1600 nm). The magnetization of all the compounds have been measured with a Quantum Design MPMS-XL operating between 2 and 300 K. For the $\chi_M T$ vs. T plots, with χ_M the molar magnetic susceptibility and T the temperature in Kelvin, two procedures have been applied depending on the amplitude of the magnetic moment. For Yb(III)-based samples a magnetic field of 2 kOe is applied below 20 K and of 10 kOe above. For Dy(III)-based samples a magnetic field of 0.2 kOe is applied below 20 K, 2 kOe between 20 and 80 K and finally 10 kOe above 80 K. All the magnetization curves have been measured at 2 K. In ac mode, an oscillating field of 3 Oe is applied at frequencies comprised between 1 and 1000 Hz with a Quantum Design MPMS-XL and between 10 and 10000 Hz with a Quantum Design PPMS. For all samples, the magnetization is corrected for intrinsic diamagnetism evaluated with Pascal's tables and the extrinsic diamagnetism of the sample holder (Teflon tape).

Details for EDS (Energy Dispersive Spectrometry) analysis: $[Dy_{(1+x)}Nd_{(1-x)}(hfac)_6(L)] \cdot 2(CH_2Cl_2) \cdot (C_6H_{14}) (15) (x = 0.21)$





Element	Type of transition	% Mass	% atomic
F	K edge	39.43	67.47
S	K edge	24.68	25.02
Nd	L edge	13.32	3.00
Dy	L edge	22.56	4.51
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.65



Element	Type of transition	% Mass	% atomic
F	K edge	55.50	78.57
S	K edge	20.65	17.32
Nd	L edge	7.82	1.46
Dy	L edge	16.03	2.65
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.55



Element	Type of transition	% Mass	% atomic
F	K edge	40.93	68.35
S	K edge	24.93	24.67
Nd	L edge	12.64	2.78
Dy	L edge	21.50	4.20
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.66



Element	Type of transition	% Mass	% atomic
F	K edge	50.52	75.32
S	K edge	22.31	19.71
Nd	L edge	10.86	2.13
Dy	L edge	16.31	2.84
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.75



Element	Type of transition	% Mass	% atomic
F	K edge	47.87	73.36
S	K edge	23.39	21.24
Nd	L edge	10.88	2.20
Dy	L edge	17.86	3.20
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.75

$[Dy_{(1+x)}Nd_{(1-x)}(tta)_{3}(hfac)_{3}(L)] (16) (x = 0.11)$



250µm



Element	Type of transition	% Mass	% atomic
F	K edge	39.21	63.98
S	K edge	31.08	30.05
Nd	L edge	12.83	2.76
Dy	L edge	16.87	3.22
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.86



Element	Type of transition	% Mass	% atomic
F	K edge	36.99	61.90
S	K edge	32.00	31.73
Nd	L edge	12.16	2.68
Dy	L edge	18.85	3.69
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.73



Element	Type of transition	% Mass	% atomic
F	K edge	30.11	56.39
S	K edge	31.30	34.73
Nd	L edge	15.33	3.78
Dy	L edge	23.26	5.09
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.74



Element	Type of transition	% Mass	% atomic
F	K edge	41.44	65.74
S	K edge	30.64	28.80
Nd	L edge	12.31	2.57
Dy	L edge	15.61	2.89
Total:		100.00	100.00
Nd/Dy ratio (1-x)/(1+x)			0.74

$[Yb_{(1+x)}Nd_{(1-x)}(hfac)_6(L)] (17) (x = 0.04)$





Element	Type of transition	% Mass	% atomic
F	K edge	34.27	63.19
S	K edge	25.56	27.92
Nd	L edge	18.54	4.50
Yb	L edge	21.64	4.38
Total:		100.00	100.00
Nd/Yb ratio (1-x)/(1+x)			1.03



Element	Type of transition	% Mass	% atomic
F	K edge	39.66	67.03
S	K edge	25.99	26.03
Nd	L edge	15.26	3.40
Yb	L edge	19.09	3.54
Total:		100.00	100.00
Nd/Yb ratio (1-x)/(1+x)			0.96



Element	Type of transition	% Mass	% atomic
F	K edge	52.26	76.48
S	K edge	21.92	19.01
Nd	L edge	11.35	2.19
Yb	L edge	14.47	2.33
Total:		100.00	100.00
Nd/Yb ratio (1-x)/(1+x)			0.94



Element	Type of transition	% Mass	% atomic
F	K edge	45.87	72.14
S	K edge	23.78	22.16
Nd	L edge	13.36	2.77
Yb	L edge	16.99	2.93
Total:		100.00	100.00
Nd/Yb ratio (1-x)/(1+x)			0.95



Element	Type of transition	% Mass	% atomic
F	K edge	27.71	57.87
S	K edge	24.43	30.23
Nd	L edge	20.32	5.59
Yb	L edge	27.54	6.31
Total:		100.00	100.00
Nd/Yb ratio (1-x)/(1+x)			0.89



Figure S1. ORTEP view of **1**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S2. ORTEP view of **3**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S3. ORTEP view of **4**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S4. ORTEP view of **6**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S5. ORTEP view of **8**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S6. Crystal packing of **3**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $M(hfac)_2$ and $Ln(hfac)_3$ are shown in ball and sticks representation.



Figure S7. Crystal packing of **4**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $M(hfac)_2$ and $Ln(hfac)_3$ are shown in ball and sticks representation.



Figure S8. Crystal packing of **6**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $M(hfac)_2$ and $Ln(hfac)_3$ are shown in ball and sticks representation.



Figure S9. Crystal packing of **8**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $M(hfac)_2$ and $Ln(hfac)_3$ are shown in ball and sticks representation.



Figure S10. ORTEP view of **11**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S11. Crystal packing of **11**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $M(hfac)_2$ and $Ln(hfac)_3$ are shown in ball and sticks representation.

The previous X-ray structures **1-10** have shown that Mn(II), Co(II), Ni(II), Zn(II) and Cd(II) can be inserted in the hetero-bimetallic complexes. The case of the insertion of a Cu(II) ion is special. In fact the coordination reaction of Cu(II) in presence of MeOH leads to the formation of a pure 3*d* complex of formula $[Cu(hfac)(CH_3OH)(L')] \cdot 0.5(C_6H_{14})$ (**12**) while in the absence of alcohol the formation of the unprecedented $[Cu(H_2O)Dy(hfac)_4(L)] \cdot [Dy(hfac)_4] \cdot (CH_2Cl_2)$ (**13**) hetero-bimetallic complex is observed (see Supporting Informations for structural descriptions and Figures S12-S15).

[Cu(hfac)(CH₃OH)(L')]-0.5(C₆H₁₄) (12). 12 crystallizes in the P-1 (N°2) triclinic space group (Table S1). The X-ray structure reveales that the alkylated dpp fragment is not anymore present leading to the conclusion that the combination Cu(II)/alcohol allowed a N-dealkylation reaction to give the ligand 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine (L'). Consequently only the bischelating site of coordination is available, it is occupied by the Cu(II) ion. The Cu(II) is coordinated to the N3 deprotonated amine and the N2 atom of the pyridine moiety (Figure S12). The negative charge of the N3 amine induced the loss of one hfac⁻ of the Cu(hfac)₂ precursor and the axial position is occupied by one MeOH molecule. The Cu(II) lies in a N₂O₃ environment which can be described as a square pyramidal polyhedron with a long Cu1-O3 distance due to the Jahn-Teller effect.



Figure S12. ORTEP view of **12**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.

The crystal packing highlights the formation of columns along the *a* axis composed of head-totail dimers (D-A dimers) and Acceptor-Acceptor (A-A) dimers (where A is the bzip fragment) (Figure S13). The D-A dimers are favored due to π - π interactions and the Cu1...S6 contacts in axial position while the A-A dimers are favored thanks to H-bonds between the coordinated MeOH and the imine of the imidazole fragment (N3...O3 = 2.784 Å).



Figure S13. Crystal packing of **12** highlighting the formation of the columns along the *a* axis. In the crystal, the columns interact through the S1…S4 contacts (3.838 Å).

[Cu(H₂O)Dy(hfac)₄(L)]·[Dy(hfac)₄]·(CH₂Cl₂) (13). 13 crystallizes in the P-1 (N°2) triclinic space group (Table S1). The asymmetric unit is composed of one [Cu(H₂O)Dy(hfac)₄(L)]⁺ cation, one [Dy(hfac)₄]⁻ anion and one dichloromethane molecule of crystallization (Figure S14). The X-ray structure reveales that the dpp coordination site is occupied by the Dy(hfac)₃ precursor as expected. Nevertheless, it also revealed that the Cu(II) remains in an N₂O₃ square pyramidal environment even if the integrity of L is conserved. The axial position is now occupied by a water molecule instead of a MeOH molecule. Since such geometry leads to the loss of one hfac⁻ anion to allow the coordination of the Cu(II) to the bischelating bzip coordination site and the Cu(II) is now coordinated to the imine nitrogen atoms of the imidazole (N1) and pyridine (N2) moieties, consequently the [Cu(H₂O)Dy(hfac)₄(L)]⁺ fragment is cationic and so a [Dy(hfac)₄]⁻ anion is formed to preserve the electro-neutrality of the complex.



Figure S14. ORTEP view of **13**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.

The $[Dy(hfac)_4]^-$ anion strongly interacts with the axial water molecule with two identified H-bonds (O1…O13 = 2.780 Å and O1…O16 = 3.007 Å). Such proximity leads to a short intermolecular distance between Cu1 and Dy2 (6.001(4) Å) compared to the M-Ln intermolecular distances observed in the other compounds (Table S4). The α angle is also

affected by the presence of the $[Dy(hfac)_4]^-$ anion with an almost orthogonality between the dpp and bzip fragments ($\alpha = 84.6(4)^\circ$) (Table S6).



Figure S15. Crystal packing of **13**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety, organometallic precursors Cu(hfac)(H₂O) and Dy(hfac)₃, and $[Dy(hfac)_4]^-$ anion are shown in ball and sticks representation.

The crystal packing is also drastically changed with the formation of isolated head-to-tail dimers along the a axis and no S···S contacts are observed (Figure S15).

The shortest intramolecular Cu-Dy and intermolecular Dy-Dy are in the same range of distances than for compounds **1-11** (Table S4).



Figure S16. Crystal packing of **14**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H* $-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors Pr(hfac)₃ are shown in ball and sticks representation.$



Figure S17. ORTEP view of **15**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S18. ORTEP view of **17**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S19. ORTEP view of **18**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S20. ORTEP view of **19**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S21. Representative crystal packing for compounds **15** and **17-19**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H*-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and the organometallic precursors $Ln(hfac)_3$ are shown in ball and sticks representation.



Figure S22. ORTEP view of **16**. Thermal ellipsoids are drawn at 30% probability. Hydrogen atoms and solvent molecules of crystallization are omitted for clarity.



Figure S23. Crystal packing of **16**. The 4,5-[4,5-bis(propylthio)-tetrathiafulvalenyl]-1*H* $-benzimidazol-2-yl}pyridine fragment is shown in spacefill representation while the dpp moiety and organometallic precursors Ln(hfac)₃ are shown in ball and sticks representation.$



Figure S24. Cyclic voltammograms of **1-13** in CH_2Cl_2 at a scan rate of 100 mV·s⁻¹. The potentials were measured *vs*. a saturated calomel electrode (SCE) with Pt wires as working and counter electrodes.



Figure S25. Cyclic voltammograms of **14-19** in CH_2Cl_2 at a scan rate of 100 mV·s⁻¹. The potentials were measured *vs*. a saturated calomel electrode (SCE) with Pt wires as working and counter electrodes.



Figure S26. Experimental UV-vis absorption spectra of compounds 3, 5, 8 and 10 in CH_2Cl_2 solution.



Figure S27. Experimental UV-vis absorption spectra of compounds 15-17 and 19 in CH₂Cl₂ solution.



Figure S28. Experimental UV-vis absorption spectra in solid-state of compounds 3, 5, 8 and 10 in KBr pellets.



Figure S29. Experimental UV-vis absorption spectra in solid-state of compounds **15-17** and **19** in KBr pellets.



Figure S30. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 3 in the solid state at room temperature.



Figure S31. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 5 in the solid state at room temperature.



Figure S32. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 8 in the solid state at room temperature.



Figure S33. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 10 in the solid state at room temperature.



Figure S34. Visible ($\lambda_{ex} = 350 \text{ nm}$) luminescence spectra of **3** in the solid state at 77 K.



Figure S35. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 5 in the solid state at 77 K.



Figure S36. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of **8** in the solid state at 77 K.



Figure S37. Visible ($\lambda_{ex} = 350 \text{ nm}$) luminescence spectra of 10 in the solid state at 77 K.



Figure S38. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 15 in the solid state at room temperature.



Figure S39. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 17 in the solid state at room temperature.



Figure S40. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 19 in the solid state at room temperature.



Figure S41. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 15 in the solid state at 77 K.



Figure S42. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of **17** in the solid state at 77 K.



Figure S43. Visible ($\lambda_{ex} = 350$ nm) luminescence spectra of 19 in the solid state at room temperature.



Figure S44. Thermal variation of $\chi_M T$ for **1**. Inset: field variation of the magnetization of **1** at 2 K.



Figure S45. Thermal variation of $\chi_M T$ for 2, 6, 7 and 9.



Figure S46. Magnetization curves at 2 K for 2, 6, 7 and 9.



Figure S47. Temperature variation of $\chi_M T$ for 3 with the field variation of the magnetization recorded at 2 K.



Figure S48. Thermal variation of $\chi_M T$ for 4 and 5.



Figure S49. Magnetization curves at 2 K for 4 and 5.



Figure S50. Thermal variation of $\chi_M T$ for 8 and 10.



Figure S51. Magnetization curves at 2 K for 8 and 10.



Figure S52. Thermal variation of $\chi_M T$ for 11 with the magnetization curve at 2 K in inset.



Figure S53. Thermal variation of $\chi_M T$ for 14.



Figure S54. Thermal variation of χ_M for **14** with the magnetization curve at 2 K in inset. The red line corresponds to the best fitted curve for χ_M vs. T (see main text).



Figure S55. Thermal variation of $\chi_M T$ and χ_M^{-1} for **15**. The red line corresponds to the best fitted curve for χ_M^{-1} vs. T with Curie-Weiss law (see main text).



Figure S56. Thermal variation of $\chi_M T$ and χ_M^{-1} for **16**. The red line corresponds to the best fitted curve for χ_M^{-1} vs. T with Curie-Weiss law (see main text).



Figure S57. Thermal variation of $\chi_M T$ and χ_M^{-1} for **17**. The red line corresponds to the best fitted curve for χ_M^{-1} vs. T with Curie-Weiss law (see main text).



Figure S58. Thermal variation of $\chi_M T$ and χ_M^{-1} for **19**. The red line corresponds to the best fitted curve for χ_M^{-1} vs. T with Curie-Weiss law (see main text).



Figure S59. Thermal variation of χ_M '' in zero external dc field for **1** at various frequencies of the oscillating field.



Figure S60. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **1** under an applied magnetic field of 1500 Oe in the temperature range 2-12 K.



Figure S61. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **2** under an applied magnetic field of 1500 Oe in the temperature range 2-15 K.



Figure S62. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **4** under an applied magnetic field of 1500 Oe in the temperature range 2-15 K.



Figure S63. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **7** under an applied magnetic field of 1500 Oe in the temperature range 2-15 K.



Figure S64. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **9** under an applied magnetic field of 1500 Oe in the temperature range 2-15 K.



Figure S65. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **11** under an applied magnetic field of 1500 Oe in the temperature range 2-15 K.



Figure S66. Normalized Cole-Cole plots for **1** at several temperatures between 2 and 9 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S67. Normalized Cole-Cole plots for **2** at several temperatures between 2 and 4.5 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S68. Normalized Cole-Cole plots for **4** at several temperatures between 2 and 6.5 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S69. Normalized Cole-Cole plots for **7** at several temperatures between 2 and 4.5 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S70. Normalized Cole-Cole plots for **11** at several temperatures between 2 and 4.5 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S71. Temperature dependence of the relaxation time for **1** at 1.5 kOe in the temperature range of 2 - 9 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in dashed blue line and dashed orange line (the parameters are given in Table S16).



Figure S72. Temperature dependence of the relaxation time for **2** at 1.5 kOe in the temperature range of 2 - 4 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in blue line and dashed orange line (the parameters are given in Table S16).



Figure S73. Temperature dependence of the relaxation time for **4** at 1.5 kOe in the temperature range of 2 - 6 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in dashed blue line and dashed orange line (the parameters are given in Table S16).



Figure S74. Temperature dependence of the relaxation time for 7 at 1.5 kOe in the temperature range of 2 - 4 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in dashed blue line and dashed orange line (the parameters are given in Table S16).



Figure S75. Temperature dependence of the relaxation time for 9 at 1.5 kOe in the temperature range of 2 - 4 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in dashed blue line and dashed orange line (the parameters are given in Table S16).



Figure S76. Temperature dependence of the relaxation time for **11** at 1.5 kOe in the temperature range of 2 - 4.5 K with the best-fitted curve (full red line) with the combination Orbach + Raman processes. The Orbach and Raman contributions to the relaxation time are respectively represented in dashed blue line and dashed orange line (the parameters are given in Table S16).



Figure S77. Frequency variation of χ_M '' for 15 at 2 K at various external dc fields.



Figure S78. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **15** under an applied magnetic field of 1500 Oe in the temperature range 2-13 K.



Figure S79. Normalized Cole-Cole plots for **15** at several temperatures between 2 and 11 K under an applied magnetic field of 1.5 kOe. Full lines are the best fitted curve with the extended Debye model.



Figure S79. Frequency dependence of the in-phase (above) and out-of phase (below) components of the magnetic susceptibility for **16** under an applied magnetic field of 3000 Oe in the temperature range 2-10 K.

Compounds	$[CdDy(hfac)_5(L)]_2$	$[ZnYb(hfac)_5(L)]_2 \cdot (CH_2Cl_2)$	$[MnDy(hfac)_5(\mathbf{L})]\cdot 2(CH_2Cl_2)$
	(1)	(3)	(4)
Formula	$C_{118}H_{70}Cd_2Dy_2F_{60}N_{16}O_{20}S_{12}$	$C_{119}H_{72}Cl_2Zn_2Yb_2F_{60}N_{16}O_{20}S_{12}$	C ₆₁ H ₃₉ Cl ₄ MnDyF ₃₀ N ₈ O ₁₀ S ₆
M / g.mol ⁻¹	4106.42	4118.36	2165.60
Crystal system	Triclinic	Triclinic	triclinic
Space group	P-1 (N°2)	P-1 (N°2)	P-1 (N°2)
Cell parameters	a = 12.700(3) Å	a = 12.640(4) Å	a = 12.813(2) Å
	b = 24.985(5) Å	b = 26.082(8) Å	b = 17.119(3) Å
	c = 26.286(5) Å	c = 26.380(8) Å	c = 19.788(4) Å
	$\alpha = 101.213(6)^{\circ}$	$\alpha = 101.645(8)^{\circ}$	$\alpha = 86.381(6)^{\circ}$
	$\beta = 99.668(5)^{\circ}$	$\beta = 90.606(9)^{\circ}$	$\beta = 89.219(6)^{\circ}$
	$\gamma = 98.737(6)^{\circ}$	$\gamma = 100.406(9)^{\circ}$	$\gamma = 76.672(6)^{\circ}$
Volume / Å ³	7917(3)	8368(5)	4215.0(14)
Cell formula units	2	2	2
T / K	150 (2)	150(2)	150(2)
Diffraction reflection	$5.83 \le 2\theta \le 54.97$	$4.16 \le 2\theta \le 55.52$	$4.12 \le 2\theta \le 55.49$
$\rho_{calc}, g.cm^{-3}$	1.723	1.641	1.706
μ, mm ⁻¹	1.490	1.701	1.427
Number of reflections	193117	276977	78615
Independent reflections	36147	38578	19393
$Fo^2 > 2\sigma(Fo)^2$	17178	18770	13489
Number of variables	2120	2058	1087
R_{int} , R_1 , wR_2	0.1721, 0.1650, 0.4257	0.2104, 0.1184, 0.2354	0.1006, 0.1338, 0.3231
CCDC numbers	1865127	1865128	1865129
a 1			
Compounds	[CoY(hfac) ₅ (L)]·(CH ₂ Cl ₂)	[CoYb(hfac) ₅ (L)]	[ZnDy(tta) ₂ (hfac) ₃ (L)]·(CH ₂ Cl ₂)
Compounds	[CoY(hfac) ₅ (L)]·(CH ₂ Cl ₂) (6)	[CoYb(hfac) ₅ (L)] (8)	$[ZnDy(tta)_2(hfac)_3(L)] \cdot (CH_2Cl_2)$ (11)
Compounds	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$
Compounds Formula M / g.mol ⁻¹	[CoY(hfac) ₅ (L)]·(CH ₂ Cl ₂) (6) C ₆₀ H ₃₇ Cl ₂ CoYF ₃₀ N ₈ O ₁₀ S ₆ 2011.07	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33
Compounds Formula M / g.mol ⁻¹ Crystal system	[CoY(hfac) ₅ (L)]·(CH ₂ Cl ₂) (6) C ₆₀ H ₃₇ Cl ₂ CoYF ₃₀ N ₈ O ₁₀ S ₆ 2011.07 Monoclinic	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic	[ZnDy(tta) ₂ (hfac) ₃ (L)]·(CH ₂ Cl ₂) (11) C ₆₆ H ₄₃ Cl ₂ ZnDyF ₂₄ N ₈ O ₁₀ S ₈ 2119.33 triclinic
Compounds Formula M / g.mol ⁻¹ Crystal system Space group	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) C ₆₀ H ₃₇ Cl ₂ CoYF ₃₀ N ₈ O ₁₀ S ₆ 2011.07 Monoclinic P2 ₁ /n (N°14)	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2)	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2)
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $\alpha = 90.682(8)^{\circ}$	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)°
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $a = 90.682(8)^{\circ}$ $\beta = 102.892(8)^{\circ}$	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)°
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $\alpha = 90.682(8)^{\circ}$ $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)° \gamma = 110.483(5)°
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2)	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $\alpha = 90.682(8)^{\circ}$ $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17)	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)° \gamma = 110.483(5)° 4495.3(15)
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° \beta = 102.892(8)° \gamma = 93.699(9)° 4335.9(17) 2	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)° \gamma = 110.483(5)° 4495.3(15) 2
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2)	[CoYb(hfac) ₅ (L)] (8) C ₅₉ H ₃₅ CoYbF ₃₀ N ₈ O ₁₀ S ₆ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $\alpha = 90.682(8)^{\circ}$ $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17) 2 150(2)	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)° $\gamma = 110.483(5)°$ 4495.3(15) 2 150(2)
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2) 2.28 $\leq 2\theta \leq 55.10$	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° \beta = 102.892(8)° \gamma = 93.699(9)° 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° \beta = 93.735(5)° \gamma = 110.483(5)° 4495.3(15) 2 150(2) 5.83 \le 20 \le 54.97
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection ρ_{cale} , g.cm ⁻³	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ $8612(2)$ 4 $150 (2)$ $2.28 \le 2\theta \le 55.10$ 1.683	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$ 1.540	$\begin{split} & [ZnDy(tta)_2(hfac)_3(L)]\cdot(CH_2Cl_2) \\ & (11) \\ & C_{66}H_{43}Cl_2ZnDyF_{24}N_8O_{10}S_8 \\ & 2119.33 \\ & triclinic \\ & P-1 (N^\circ 2) \\ & a = 13.226(3) \text{ Å} \\ & b = 17.850(3) \text{ Å} \\ & c = 21.031(4) \text{ Å} \\ & \alpha = 102.119(5)^\circ \\ & \beta = 93.735(5)^\circ \\ & \gamma = 110.483(5)^\circ \\ & 4495.3(15) \\ & 2 \\ & 150(2) \\ & 5.83 \leq 2\theta \leq 54.97 \\ & 1.566 \end{split}$
Compounds Formula $M / g.mol^{-1}$ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection $\rho_{cale}, g.cm^{-3}$ μ, mm^{-1}	$\begin{split} & [\text{CoY}(\text{hfac})_5(\mathbf{L})] \cdot (\text{CH}_2\text{Cl}_2) \\ & (6) \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ $	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° $\beta = 102.892(8)°$ $\gamma = 93.699(9)°$ 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$ 1.540 1.524	$\begin{split} & [ZnDy(tta)_2(hfac)_3(L)]\cdot(CH_2Cl_2) \\ & (11) \\ & C_{66}H_{43}Cl_2ZnDyF_{24}N_8O_{10}S_8 \\ & 2119.33 \\ & triclinic \\ & P-1 (N^\circ 2) \\ & a = 13.226(3) \text{ Å} \\ & b = 17.850(3) \text{ Å} \\ & c = 21.031(4) \text{ Å} \\ & \alpha = 102.119(5)^\circ \\ & \beta = 93.735(5)^\circ \\ & \gamma = 110.483(5)^\circ \\ & 4495.3(15) \\ & 2 \\ & 150(2) \\ & 5.83 \leq 2\theta \leq 54.97 \\ & 1.566 \\ & 1.440 \end{split}$
Compounds Formula $M / g.mol^{-1}$ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection $\rho_{calc}, g.cm^{-3}$ μ, mm^{-1} Number of reflections	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2) 2.28 $\leq 2\theta \leq 55.10$ 1.683 1.256 62407	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° β = 102.892(8)° γ = 93.699(9)° 4335.9(17) 2 150(2) 1.95 \leq 20 \leq 55.12 1.540 1.524 88634	$\begin{split} & [ZnDy(tta)_2(hfac)_3(\mathbf{L})]\cdot(CH_2Cl_2) \\ & (11) \\ & C_{66}H_{43}Cl_2ZnDyF_{24}N_8O_{10}S_8 \\ & 2119.33 \\ & triclinic \\ P-1 (N^\circ 2) \\ & a = 13.226(3) \text{ Å} \\ & b = 17.850(3) \text{ Å} \\ & c = 21.031(4) \text{ Å} \\ & \alpha = 102.119(5)^\circ \\ & \beta = 93.735(5)^\circ \\ & \gamma = 110.483(5)^\circ \\ & 4495.3(15) \\ & 2 \\ & 150(2) \\ & 5.83 \leq 2\theta \leq 54.97 \\ & 1.566 \\ & 1.440 \\ & 82862 \end{split}$
Compounds Formula $M / g.mol^{-1}$ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection ρ_{cale} , g.cm ⁻³ μ , mm ⁻¹ Number of reflections Independent reflections	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2) 2.28 $\leq 2\theta \leq 55.10$ 1.683 1.256 62407 18545	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$ 1.540 1.524 88634 18906	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° $\beta = 93.735(5)°$ $\gamma = 110.483(5)°$ 4495.3(15) 2 150(2) 5.83 $\leq 20 \leq 54.97$ 1.566 1.440 82862 20454
Compounds Formula M / g.mol ⁻¹ Crystal system Space group Cell parameters Volume / Å ³ Cell formula units T / K Diffraction reflection ρ_{cale} , g.cm ⁻³ μ , mm ⁻¹ Number of reflections Independent reflections Fo ² > 2\sigma(Fo) ²	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2) 2.28 $\leq 2\theta \leq 55.10$ 1.683 1.256 62407 18545 5686	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å $\alpha = 90.682(8)^{\circ}$ $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$ 1.540 1.524 88634 18906 6583	$\begin{split} & [\text{ZnDy(tta)}_2(\text{hfac})_3(\text{L})] \cdot (\text{CH}_2\text{Cl}_2) \\ & (\textbf{11}) \\ & \textbf{C}_{66}\text{H}_{43}\text{Cl}_2\text{ZnDy}\text{F}_{24}\text{N}_8\text{O}_{10}\text{S}_8 \\ & 2119.33 \\ & \text{triclinic} \\ & \textbf{P}-1 (\text{N}^\circ\text{2}) \\ & \textbf{a} = 13.226(3) \text{ Å} \\ & \textbf{b} = 17.850(3) \text{ Å} \\ & \textbf{c} = 21.031(4) \text{ Å} \\ & \textbf{a} = 102.119(5)^\circ \\ & \textbf{\beta} = 93.735(5)^\circ \\ & \textbf{\gamma} = 110.483(5)^\circ \\ & 4495.3(15) \\ & \textbf{2} \\ & 150(2) \\ & 5.83 \leq 2\theta \leq 54.97 \\ & 1.566 \\ & 1.440 \\ & 82862 \\ & 20454 \\ & 5657 \end{split}$
$\begin{tabular}{ c c c } \hline Compounds & & \\ \hline Formula & & \\ M / g.mol^{-1} & & \\ Crystal system & & \\ Space group & & \\ Cell parameters & & \\ \hline Cell parameters & & \\ \hline Cell formula units & & \\ T / K & & \\ Diffraction reflection & & \\ \rho_{calc}, g.cm^{-3} & & \\ \mu, mm^{-1} & & \\ Number of reflections & \\ Independent reflections & \\ Fo^2 > 2\sigma(Fo)^2 & \\ Number of variables & \\ \hline \end{tabular}$	$[CoY(hfac)_{5}(L)] \cdot (CH_{2}Cl_{2})$ (6) $C_{60}H_{37}Cl_{2}CoYF_{30}N_{8}O_{10}S_{6}$ 2011.07 Monoclinic $P2_{1}/n (N^{\circ}14)$ $a = 13.189(2) \text{ Å}$ $b = 16.340(3) \text{ Å}$ $c = 40.379(7) \text{ Å}$ $\beta = 98.251(4)^{\circ}$ 8612(2) 4 150 (2) 2.28 $\leq 2\theta \leq 55.10$ 1.683 1.256 62407 18545 5686 1140	$[CoYb(hfac)_{5}(L)]$ (8) $C_{59}H_{35}CoYbF_{30}N_{8}O_{10}S_{6}$ 2010.28 triclinic P-1 (N°2) a = 12.664(3) Å b = 16.455(4) Å c = 21.398(5) Å a = 90.682(8)° $\beta = 102.892(8)^{\circ}$ $\gamma = 93.699(9)^{\circ}$ 4335.9(17) 2 150(2) 1.95 $\leq 2\theta \leq 55.12$ 1.540 1.524 88634 18906 6583 1074	$[ZnDy(tta)_{2}(hfac)_{3}(L)] \cdot (CH_{2}Cl_{2})$ (11) $C_{66}H_{43}Cl_{2}ZnDyF_{24}N_{8}O_{10}S_{8}$ 2119.33 triclinic P-1 (N°2) a = 13.226(3) Å b = 17.850(3) Å c = 21.031(4) Å a = 102.119(5)° $\beta = 93.735(5)°$ $\gamma = 110.483(5)°$ 4495.3(15) 2 150(2) 5.83 $\leq 2\theta \leq 54.97$ 1.566 1.440 82862 20454 5657 1073

Table S1. X-ray	crystallographic	data for the	complexes	1, 3, 4, 6,	8, 11-13.

CCDC numbers	1865131	1865133 1865134	
Compounds	$[Cu(hfac)(CH_3OH)(L)] \cdot 0.5(C_6H_{14})$	$[Cu(H_2O)Dy(hfac)_4(L)]\cdot[Dy(hfac)_4]$	
	(12)	(CH_2Cl_2) (13)	
Formula	$C_{31}H_{31}CuF_6N_1O_3S_6\\$	$C_{75}H_{42}Cl_2CuDy_2F_{48}N_8O_{17}S_6$	
$M / g.mol^{-1}$	863.54	2888.95	
Crystal system	Triclinic	Triclinic	
Space group	P-1 (N°2)	P-1 (N°2)	
Cell parameters	a = 9.7341(18) Å	a = 14.501(4) Å	
	b = 13.820(3) Å	b = 19.225(6) Å	
	c = 15.588(3) Å	c = 20.545(6) Å	
	$\alpha = 113.594(6)^{\circ}$	$\alpha = 91.777(10)^{\circ}$	
	$\beta = 107.762(6)^{\circ}$	$\beta = 103.902(9)^{\circ}$	
	$\gamma = 93.416(6)^{\circ}$	$\gamma = 111.996(9)^{\circ}$	
Volume / Å ³	1790.0(6)	5108(3)	
Cell formula units	2	2	
T / K	150	150	
Diffraction reflection	$4.43 \le 2\theta \le 54.89$	$5.83 \le 2\theta \le 54.97$	
ρ_{calc} , g.cm ⁻³	1.602	1.878	
μ, mm ⁻¹	1.029	1.981	
Number of reflections	36206	103507	
Independent reflections	8146	23325	
$Fo^2 > 2\sigma(Fo)^2$	5127	16423	
Number of variables	442	1427	
R_{int}, R_1, wR_2	0.0814, 0.0707, 0.1821	0.1656, 0.2073, 0.5031	
CCDC numbers	1865130	1865132	

Table S2. X-ray crystallographic data for the complexes 14-19.

Compounds	$[\Pr(hfac)_{3}(\mathbf{L})]_{2} \cdot 0.5(C_{6}H_{14})$ (14)	$[Dy_{1.21}Nd_{0.79}(hfac)_6(L)]$	$[Dy_{1.11}Nd_{0.89}(tta)_3(hfac)_3(L)]$
		$2(CH_2Cl_2) \cdot (C_6H_{14})$ (15)	(16)
Formula	$C_{101}H_{73}Pr_2F_{36}N_{16}O_{12}S_{12}$	$C_{72}H_{54}Cl_4Dy_{1.21}Nd_{0.79}F_{36}N_8O_{12}S_6$	$C_{73}H_{45}Dy_{1.11}Nd_{0.89}F_{27}N_8O_{12}S_9$
M / g.mol ⁻¹	3053.3	2550.57	2336.46
Crystal system	monoclinic	monoclinic	Triclinic
Space group	C2/c (N°15)	$P2_1/n (N^{\circ}14)$	P-1 (N°2)
	a = 42.278(14) Å	a = 22.440(2) Å	a = 10.170(2) Å
	b = 11.697(4) Å	b = 12.6945(12) Å	b = 16.139(3) Å
Cell parameters	c = 50.539(17) Å	c = 33.791(3) Å	c = 30.871(6) Å
			$\alpha = 97.354(6)^{\circ}$
	$\beta = 92.934(4)^{\circ}$	$\beta = 100.983(3)^{\circ}$	$\beta = 91.253(6)^{\circ}$
			$\gamma = 99.875(6)^{\circ}$
Volume / Å ³	24960(14)	9449.7(16)	4946.0(17)
Cell formula units	2	4	2
T / K	150 (2)	150(2)	150(2)
Diffraction reflection	$5.45 \le 2\theta \le 55.35$	$5.86 \le 2\theta \le 54.97$	$5.83 \le 2\theta \le 54.96$
$\rho_{calc}, g.cm^{-3}$	1.636	1.794	1.569
μ, mm ⁻¹	1.099	1.765	1.590
Number of reflections	72888	103333	83873
Independent reflections	29067	20831	21407

$Fo^2 > 2\sigma(Fo)^2$	10203	17401	12845	
Number of variables	1535	1214	1178	
R_{int}, R_1, wR_2	0.2119, 0.1293, 0.2889	0.0689, 0.1172, 0.2726	0.0985, 0.1494, 0.3369	
CCDC numbers	1865135	1865136	1865138	
Compounds	$[\mathbf{V}\mathbf{h} \mathbf{N}\mathbf{d} (\mathbf{h}\mathbf{f}\mathbf{n}\mathbf{a}) (\mathbf{I})]$	$[Nd (hfree) (\mathbf{I})] (\mathbf{C} \mathbf{H})$	$[\mathbf{V}\mathbf{h}\mathbf{D}\mathbf{r}(\mathbf{h}\mathbf{f}_{n,n}) (\mathbf{I}_{n})]$	
Compounds	$[10_{1.041} vu_{0.96} (\text{IIIac})_6 (\mathbf{L})]$	$[100_2(11aC)_6(L)] \cdot (C_6H_{14})$	$[10F(\operatorname{IIIac})_6(\mathbf{L})]$	
	(17)	(18)	(19)	
Formula	$C_{64}H_{36}Yb_{1.04}Nd_{0.96}F_{36}N_8O_{12}S_6$	$C_{70}H_{50}Nd_2F_{36}N_8O_{12}S_6$	$C_{64}H_{36}YbPrF_{36}N_8O_{12}S_6$	
M / g.mol ⁻¹	2303.80	2360.02	2299.32	
Crystal system	Monoclinic	monoclinic	monoclinic	
Space group	P2 ₁ /n (N°14)	$P2_1/n$ (N°2)	$P2_{1}/n (N^{\circ}2)$	
	a = 22.2669(16) Å	a = 22.811(4) Å	a = 22.487(5) Å	
	b = 12.6525(9) Å	b = 12.634(2) Å	b = 12.711(2) Å	
Cell parameters	c = 33.194(2) Å	c = 31.848(6) Å	c = 33.458(7) Å	
	$\beta = 99.920(2)^{\circ}$	$\beta = 103.311(5)^{\circ}$	$\beta = 100.768(7)^{\circ}$	
Volume / Å ³	9212.0(11)	8932(3)	9395(3)	
Cell formula units	4	4	4	
T / K	150 (2)	150(2)	150(2)	
Diffraction reflection	$4.292 \leq 2\theta \leq 55.16$	$5.94 \le 2\theta \le 54.96$	$5.94 {\leq} 2\theta {\leq} 54.96$	
$\rho_{calc}, g.cm^{-3}$	1.660	1.755	1.626	
μ, mm ⁻¹	1.830	1.425	1.731	
Number of reflections	116477	113102	69279	
Independent reflections	21085	20331	20218	
$Fo^2 > 2\sigma(Fo)^2$	11609	6634	12433	
Number of variables	1323	1155	1140	
R_{int}, R_1, wR_2	0.0745, 0.1339, 0.3397	0.5182, 0.1417, 0.2339	0.1091, 0.2464, 0.5190	
CCDC numbers	1865140	1865139	1865137	

Compounds	$[ZnDy(hfac)_5(L)]\cdot 2(CH_2Cl_2)\cdot (C_6H_{14})$	[MnYb(hfac) ₅ (L)]·2(CH ₂ Cl ₂)	$[CoDy(hfac)_5(L)]\cdot 2(CH_2Cl_2)\cdot (C_6H_{14})$
	(2)	(5)	(7)
Formula	$C_{67}H_{53}Cl_4ZnDyF_{30}N_8O_{10}S_6$	$C_{61}H_{39}Cl_4MnYbF_{30}N_8O_{10}S_6$	$C_{67}H_{53}Cl_4CoDyF_{30}N_8O_{10}S_6$
M / g.mol ⁻¹	2260.90	2166.38	2255.77
Crystal system	Monoclinic	Triclinic	Monoclinic
	a = 13.0349(50) Å	a = 12.6744(19) Å	a = 13.0886(24) Å
	b = 16.0719(67) Å	b = 17.2322(26) Å	b = 16.1922(30) Å
Cell parameters	c = 40.5385(143) Å	c = 19.7161(29) Å	c = 40.6329(76) Å
		$\alpha = 93.2236(54)^{\circ}$	
	$\beta = 98.7432(113)^{\circ}$	0 01 2040(54)9	$\beta = 99.1885(46)^{\circ}$
		$\beta = 91.3049(54)^{2}$	
Value (Å3	8202 04(012)	$\gamma = 104.0000(01)^{-1}$	8500 05(457)
volume / A ²	8393.94(912)	4157.34(170)	8500.95(457)
	4	2	4
1 / K 20. manuala /9	150(2)	150(2)	150(2)
20 range /°	$4.74 \le 20 \le 38.96$	$4.68 \le 20 \le 37.92$	$4.72 \le 20 \le 37.22$
Number of reflections	9185	5975	9906
Common da			
Compounds	$[N_1Dy(hfac)_5(\mathbf{L})]\cdot 2(CH_2Cl_2)\cdot (C_6H_{14})$	$[N1 Y D(\Pi aC)_5(\mathbf{L})]$	
Formula	$C_{67}H_{53}Cl_4N_1DyF_{30}N_8O_{10}S_6$	$C_{59}H_{35}N_1YbF_{30}N_8O_{10}S_6$	
M / g.mol ⁻¹	2255.57	2010.08	
Crystal system	Monoclinic	Triclinic	
Cell parameters	a = 13.1928(18) A	a = 12.7539(33) A	
	b = 16.1446(23) A	b = 16.3134(45) A	
	c = 39.8516(59) A	c = 21.1691(56) A	
		$\alpha = 90.6833(80)^{\circ}$	
	$\beta = 98.7085(46)^{\circ}$	$\beta = 102.7846(76)^{\circ}$	
		$\gamma = 94.2735(83)^{\circ}$	
Volume / Å ³	8390 22(357)	4281 48(325)	
7	4	2	
T / K	150(2)	150(2)	
2θ range /°	4.72 < 20 < 37.22	4.54 < 20 < 29.22	
Number of reflections		9872	

Table S3.	Cell	parameters :	for the	compounds	2, 5	5, 7, 9) and 1	0.
-----------	------	--------------	---------	-----------	------	---------	----------------	----

Table S4. Selected intra- and inter-molecular bond lengths (Å) for complexes 1, 3, 4, 6, 8, 11and 13.

	Average	Average	Average	Average	Intramolecular	Intermolecular	Intermolecular
	d(M-O)/Å	d(M-N)/Å	d(Ln-O)/Å	d(Ln-N)/Å	d(Ln-M)/Å	d(Ln-M)/Å	d(Ln-Ln)/Å
1	2.290(13)	2.303(14)	2.375(12)	2.515(11)	10.221(3)	8.868(2)	8.129(2)
	2.268(15)	2.279(18)	2.343(14)	2.518(18)	10.766(3)	9.003(2)	8.419(2)
							8.917(2)
3	2.102(9)	2.102(11)	2.330(10)	2.482(10)	9.723(3)	9.271(3)	8.716(2)
	2.088(9)	2.109(11)	2.321(9)	2.494(11)	10.676(4)	10.394(3)	9.947(2)
							10.255(2)
4	2.159(11)	2.226(12)	2.374(10)	2.535(10)	10.658(3)	9.072(3)	8.656(2)
6	2.047(13)	2.098(14)	2.344(13)	2.493(14)	10.104(3)	9.468(3)	10.283(3)
8	2.069(11)	2.074(13)	2.343(10)	2.480(13)	10.018(3)	10.631(3)	9.900(2)
11	2.117(13)	2.147(16)	2.365(11)	2.561(11)	10.005(3)	11.206(3)	8.989(2)
13	2.043(20)	1.990(25)	2.373(21)	2.510(30)	10.052(6)	5.989(4)	8.519(3)
			2.328(21)	/			

Table S5. SHAPE analyses of the coordination polyhedra around the lanthanide ion incomplexes 1, 3, 4, 6, 8, 11 and 14.

	Metal	CShM _{TCTPR-9}	CShM _{CSAPR-9}	CShM _{MFF-9}
		(Spherical tricapped	(Spherical capped	(Muffin C _s)
		trigonal prism D _{3h})	square antiprism C _{4v})	
1	Dy1	0.942	0.936	1.402
1	Dy2	1.313	0.553	0.931
3	Yb1	1.178	0.497	0.795
5	Yb2	0.434	0.904	1.551
4	Dy1	1.512	0.708	0.995
6	Y1	0.901	0.854	1.040
8	Yb1	0.466	0.909	1.419
11	Dy1	0.790	1.081	1.474
14	Pr1	1.117	1.828	1.920
	Pr2	2.467	1.884	1.319

Table S6. Selected short contacts (Å) and angles (°) for complexes 1, 3, 4, 6, 8, 11 and 13.

	α/Å	Short
		contacts/Å
		S11····O2=3.058
	74.4(4)	S11S3=3.381
1	54.8(6)	S11S4=3.681
		S10S5=3.787
		S10S6=3.691
	76.2(3)	\$9\$5=3.690
3	65.6(3)	S10S6=3.743
		S11S3=3.597
		S12····S4=3.654
4	69.7(4)	S5S3=3.748
		S6…S4=3.759
6	76.4(4)	\$5\$3=3.796
		S6…S4=3.626
8	69.8(4)	S5S3=3.641
		S6…S4=3.569
11	67.7(4)	\$5\$3=3.706
		S6…S4=3.680
13	84.6(4)	S8S8=3.967

	Average	Average	Average	Average	Intramolecular	Intermolecular
	d(Ln*-O)/Å	d(Ln*-N)/Å	d(Ln-O)/Å	d(Ln-N)/Å	d(Ln-Ln)/Å	d(Ln-Ln)/Å
14	2.474(11)	2.647(12)	/	/	/	9.592(3)
	2.483(11)	2.650(12)				
15	2.414(10)	2.573(11)	2.347(9)	2.547(10)	10.895(4)	9.690(3)
16	2.429(13)	2.597(14)	2.345(11)	2.521(12)	10.242(4)	8.613(2)
17	2.406(16)	2.619(11)	2.348(11)	2.541(10)	10.767(4)	9.098(3)
18	2.433(16)	2.623(16)	2.419(14)	2.623(13)	10.890(4)	8.259(3)
19	2.447(19)	2.620(19)	2.306(17)	2.540(19)	10.859(4)	9.534(2)
Dy2	2.362	2.527	2.339	2.527		
Yb2	2.333	2.487	2.295	2.490		

Table S7. Selected intra- and inter-molecular bond lengths (Å) for complexes 14-19.

* Lanthanide ion in the N₃O₉ coordination site.

Table S8. Selected short contacts (Å) and angles (°) for complexes 14-19.

	α/Å	Short contacts/Å		
		S4…S9 = 3.714		
14	86.1(3)	S4S10 = 3.719		
	86.2(4)	S5 - S11 = 3.714		
		$S5 \cdots S12 = 3.732$		
15	76.1(3)	S3···S6=3.785		
16	73.5(3)	S4…S6=3.672		
17	72.6(3)	S3···S6=3.649		
18	77.9(5)	S4S5=3.595		
19	80.8(5)	S4…S5=3.750		

 Table S9. SHAPE analyses of the coordination polyhedra around the lanthanide ion in complexes 15-19.

	Metal	CShM _{SAPR-8} (square antiprism D _{4d})	$\begin{array}{c} CShM_{TDD-8} \\ (triangular \\ dodecahedron \\ D_{2d}) \end{array}$	$CShM_{BTPR-8}$ (biaugmented trigonal prism C_{2v})	CShM _{TCTPR-9} (spherical tricapped trigonal prism D _{3h})	CShM _{CSAPR-9} (spherical capped square antiprism	CShM _{MFF-9} (Muffin C _s)
	Dr.1	0.487	2 707	2 502		C4V)	
15	Nd1/Dy2	-	-	-	0.663	- 1.111	- 1.435
16	Dy1	0.908	1.796	1.744	-	-	-
10	Nd1/Dy2	-	-	-	0.577	0.981	1.486
17	Yb1	0.540	2.623	2.403	-	-	-
17	Nd1/Yb2	-	-	-	0.911	1.097	1.308
18	Nd1	0.627	2.515	2.543	-	-	-
10	Nd2	-	-	-	0.877	0.844	1.432
19	Yb1	0.439	2.773	2.399	-	-	-
	Pr1	-	-	-	0.785	1.198	1.621

Table S10. Oxidation potentials (V *vs* SCE, nBu₄NPF₆, 0.1 M in CH₂Cl₂ at 100 mV.s⁻¹) of the complexes **1-19**.

	$E^{1}_{1/2}$	$_2$ / V	$E^{2}_{1/2}$	2 / V
	$^{Ox}E^{1}_{1/2}$	$^{\text{Red}}E^{1}_{1/2}$	$^{Ox}E^{2}_{1/2}$	$^{\text{Red}}\text{E}^2_{1/2}$
1	0.58	0.46	0.98	0.82
2	0.60	0.51	1.01	0.88
3	0.55	0.44	0.99	0.82
4	0.58	0.46	0.97	0.84
5	0.60	0.45	1.01	0.84
6	0.64	0.45	1.02	0.86
7	0.65	0.45	1.03	0.86
8	0.59	0.48	1.01	0.92
9	0.66	0.49	1.07	0.91
10	0.63	0.52	1.05	0.93
11	0.64	0.44	1.07	0.86
12	0.54	0.45	1.01	0.88
13	0.64	0.49	1.05	0.89
14	0.71	0.63	0.97	0.89
15	0.56	0.46	0.96	0.85
16	0.56	0.47	0.99	0.89
17	0.56	0.38	1.00	0.85
18	0.55	0.45	0.98	0.87
19	0.56	0.47	0.99	0.85

Table S11. Best fitted parameters (χ_T , χ_S , τ and α) with the extended Debye model for compound **1** at 1500 Oe in the temperature range 2-9 K.

T/K	$\chi_T / \mathrm{cm}^3 \mathrm{mol}^{-1}$	$\chi_{\rm S}$ / cm ³ mol ⁻¹	α	au / s	R ²
2	5.74167	0.2865	0.39965	0.06397	0.99735
2.2	5.07811	0.31597	0.36742	0.0428	0.99725
2.4	4.50752	0.31958	0.34128	0.02813	0.99707
2.6	4.15552	0.30284	0.3244	0.02001	0.99737
2.8	3.81778	0.32359	0.29646	0.01447	0.99734
3	3.53908	0.32439	0.27252	0.01061	0.99796
3.5	2.98794	0.32866	0.22123	0.00535	0.99756
4	2.6487	0.31245	0.20617	0.00301	0.99891
4.5	2.37043	0.28171	0.19205	0.00178	0.99837
5	2.13267	0.31976	0.15966	0.00117	0.999
5.5	1.94718	0.29458	0.15437	7.76007E-4	0.99921
6	1.78497	0.29755	0.14279	5.42872E-4	0.99904
7	1.5342	0.31015	0.10887	3.04707E-4	0.99974
8	1.3463	0.33335	0.08695	1.8804E-4	0.99951
9	1.20629	0.38124	0.07992	1.21983E-4	0.99849

Table S12. Best fitted parameters (χ_T , χ_S , τ and α) with the extended Debye model for
compound 2 at 1500 Oe in the temperature range 2-4 K.

T/K	χ_T / cm ³ mol ⁻¹	χ_S / cm ³ mol ⁻¹	α	au / s	R ²
2	0.10428	0.573	0.39965	0.06397	0.99735
2.2	0.13473	0.63194	0.36742	0.0428	0.99725
2.4	0.11045	0.63916	0.34128	0.02813	0.99707
2.6	0.11628	0.60569	0.3244	0.02001	0.99737
2.8	0.0598	0.64717	0.29646	0.01447	0.99734
3	0.0617	0.64877	0.27252	0.01061	0.99796
3.5	0.0038	0.65732	0.22123	0.00535	0.99756
4	0.00121	0.62489	0.20617	0.00301	0.99891

Table S13. Best fitted parameters (χ_T , χ_S , τ and α) with the extended Debye model for compound **4** at 1500 Oe in the temperature range 2-6.5 K.

T/K	$\chi_T / \mathrm{cm}^3 \mathrm{mol}^{-1}$	$\chi_S / \mathrm{cm}^3 \mathrm{mol}^{-1}$	α	au / s	R ²
2	8.68446	2.22778	0.60558	0.0031	0.99996
2.2	7.39879	2.70677	0.48646	0.00306	0.99996
2.4	6.78453	2.63043	0.4442	0.00252	0.99998
2.6	6.27691	2.56915	0.39582	0.00209	0.99994
2.8	5.87255	2.4536	0.36616	0.00177	0.99992
3	5.51625	2.33696	0.34328	0.00151	0.99991
3.5	4.7828	2.20781	0.26189	0.00116	0.99991
4	4.2342	1.95039	0.23555	7.76975E-4	0.99989
4.5	3.80447	1.7619	0.20807	5.6667E-4	0.99991
5	3.43519	1.64762	0.18245	4.1745E-4	0.9999
5.5	3.14067	1.43666	0.18582	2.85705E-4	0.9999
6	2.88395	1.3657	0.16602	2.17276E-4	0.99992
6.5	2.48511	1.20961	0.14519	1.27156E-4	0.99992

Table S14. Best fitted parameters (χ_T , χ_S , τ and α) with the extended Debye model for

compound **7** at 1500 Oe in the temperature range 2-4 K.

T/K	χ_T / cm ³ mol ⁻¹	χ_S / cm ³ mol ⁻¹	α	au / s	R ²
2	5.85941	0.88878	0.3624	0.08478	0.99925
2.2	5.35024	0.97461	0.32681	0.08041	0.99882
2.4	4.98382	1.15039	0.27966	0.0481	0.99943
2.6	4.6802	1.07909	0.27301	0.03799	0.99951
2.8	4.52946	0.87925	0.3065	0.03278	0.99962
3	4.23086	0.81738	0.28879	0.02845	0.99958
3.5	3.71686	0.6043	0.28288	0.01851	0.99978
4	3.31412	0.36234	0.30653	0.01956	0.99948

Table S15. Best fitted parameters (χ_T , χ_S , τ and α) with the extended Debye model for compound **11** at 1500 Oe in the temperature range 2-4.5 K.

T/K	$\chi_T / \mathrm{cm}^3 \mathrm{mol}^{-1}$	χ_S / cm ³ mol ⁻¹	α	au / s	R ²
2	5.26007	0.21482	0.32753	0.00106	0.99986
2.2	4.91727	0.24516	0.32705	8.60562E-4	0.99986
2.4	4.56367	0.26842	0.33191	6.60046E-4	0.99983
2.6	4.27844	0.25961	0.33122	5.1069E-4	0.99989
2.8	4.02019	0.31684	0.331	4.15771E-4	0.99989
3	3.79369	0.29642	0.34117	3.19953E-4	0.99991
3.5	3.31336	0.42175	0.33377	2.04467E-4	0.99992
4	2.94674	0.45434	0.34921	1.25088E-4	0.99994
4.5	2.64968	0.54061	0.34784	8.93361E-5	0.99992

Table S16. Best fitted parameters (χ_T , χ_S , τ_I , τ_2 , α and β) with the extended Debye model for compound **15** at 1500 Oe in the temperature range 2-12 K. τ_I and τ_2 are the two relaxation times and β the ratio between the these two processes amplitude.

T/K	χ_T / cm ³ mol ⁻¹	χ_S / cm ³ mol ⁻¹	β	$ au_l$ / s	$ au_2$ / s	α	R ²
2	0.29098	9.71031	0.71674	1.20776	0.00147	0.49133	0.99991
2.2	0.33675	9.16813	0.72201	1.05834	0.00129	0.48042	0.99991
2.4	0.40459	7.54444	0.70305	0.47535	9.85863E-4	0.44512	0.99991
2.6	0.40065	6.90708	0.70129	0.34022	7.50432E-4	0.43166	0.99994
2.8	0.42787	6.34207	0.70373	0.23943	5.95928E-4	0.41633	0.9999
3	0.46974	5.79555	0.70424	0.16428	5.00198E-4	0.39284	0.99994
3.5	0.5448	4.91337	0.71722	0.08112	3.37201E-4	0.35028	0.99996
4	0.58094	4.26523	0.73301	0.04274	2.22346E-4	0.31635	0.99994
4.5	0.58303	3.78414	0.74005	0.02527	1.60362E-4	0.28558	0.99993
5	0.31324	3.42732	0.71 (fixed)	0.01503		0.28888	0.99973
5.5	0.31759	3.10998	0.71 (fixed)	0.00988		0.26658	0.99979
6	0.32595	2.85059	0.71 (fixed)	0.00678		0.2513	0.99975
7	0.36286	2.44538	0.71 (fixed)	0.00351		0.22921	0.99975
8	0.44256	2.14006	0.71 (fixed)	0.00197		0.20916	0.99983
9	0.55738	1.89957	0.71 (fixed)	0.00114		0.18777	0.99983
10	0.84504	1.72001		5.01853E-4		0.23088	0.99986
11	0.89023	1.56452		2.67254E-4		0.21843	0.9999
12	0.93013	1.42503		1.34871E-4		0.20637	0.99997

Compounds		Orba	ach	Raman		
		τ_0 / s	Δ / K	$C / s^{-1}K^{-n}$	n	
1		5.84(11)×10 ⁻⁵	21.1(7)	0.94(3)	4.03(3)	
2		1.50(89)×10 ⁻⁸	31.8(25)	392.2(56)	2.46(19)	
4		3.64(66)×10 ⁻⁶	25.9(12)	81.6(73)	1.55(11)	
7	,	6.82(39)×10 ⁻⁸	26.7(24)	405.1(16)	1.36(55)	
9)	3.18(34)×10 ⁻⁸	31.7(47)	1598.8(87)	2.18(7)	
1	1	3.84(76)×10 ⁻⁶	16.0(22)	233(111)	1.86(80)	
15	Dy1	/	/	0.03(1)	4.77(10)	
	Dy2	/	/	90.45(6)	2.81(6)	
16		3.07(24)×10 ⁻⁴	13.4(5)	/	/	

Table S17. Parameters of the magnetic relaxation processes for the heterobimetallic compounds.

References

1 M. F. Richardson, W. F. Wagner and D. E. Sands, J. Inorg. Nucl. Chem., 1968, 30, 1275-1289.

2 A. I. Vooshin, N. M. Shavaleev and V. P. Kazakov, J. Lumin. 2000, **91**, 49-58.

M. Feng, F. Pointillart, B. Lefeuvre, V. Dorcet, S. Golhen, O. Cador and L. Ouahab, *Inorg. Chem.*, 2015, 54, 4021-4028.
G. M. Sheldrick, *Acta Crystallogr., Sect. A Found Adv.*, 2015, 71, 3–8.
G. M. Sheldrick, *Acta Crystallogr. Sect. C*, 2015, 71, 3-8.
A. L. Spek, *J. Appl. Crystallogr.*, 2003, 36, 7-13.